Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...

A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.

In Budget 2024, the government slashed GST (Goods and Services Tax) from three major cancer drugs: Trastuzumab Deruxtecan, ...

Brain metastases are a common problem in patients with EGFR-mutated non-small cell lung cancer (NSCLC), occurring in about one-fifth to one-quarter of patients. Many brain metastases will be ...

“The amivantamab and lazertinib combination has shown significant progression-free survival improvements in patients with previously untreated EGFR-mutated advanced NSCLC, including those with brain ...